Private Profits versus Public Policy : : The Pharmaceutical Industry and the Canadian State / / Joel Lexchin.
The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren’t the interests of the public supposed to supersede the pursuit of private profit?In his new work, Private P...
Saved in:
Superior document: | Title is part of eBook package: De Gruyter University of Toronto Press Complete eBook-Package 2016 |
---|---|
VerfasserIn: | |
Place / Publishing House: | Toronto : : University of Toronto Press, , [2018] ©2016 |
Year of Publication: | 2018 |
Language: | English |
Online Access: | |
Physical Description: | 1 online resource (384 p.) :; 6 figures |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
9781442619609 |
---|---|
ctrlnum |
(DE-B1597)498620 |
collection |
bib_alma |
record_format |
marc |
spelling |
Lexchin, Joel, author. aut http://id.loc.gov/vocabulary/relators/aut Private Profits versus Public Policy : The Pharmaceutical Industry and the Canadian State / Joel Lexchin. Toronto : University of Toronto Press, [2018] ©2016 1 online resource (384 p.) : 6 figures text txt rdacontent computer c rdamedia online resource cr rdacarrier text file PDF rda Frontmatter -- Contents -- List Of Boxes, Figures, And Tables -- Preface -- Abbreviations -- Private Profits Versus Public Policy The Pharmaceutical Industry And The Canadian State -- Introduction: Why Do We Care About The Pharmaceutical Industry In Canada? -- 1.(De)Regulation Through Cooperation -- 2. Biased Testing, Hidden Results, And The Regulation Of Clinical Trials -- 3. Approving New Drugs: Better Or Just More? -- 4. Regulating Promotion Or Licensing Deception? -- 5. Health Canada And Drug Safety: How Safe Are We? -- 6. Is Intellectual Property A Right? -- 7. How Revenue Is Generated: Prices, Volume, Mix, And Overall Spending -- 8. Who Gets The Value From Research And Development? -- 9. Canada, The Pharmaceutical Industry, And Access To Medicines In The Global South -- 10. Courage, My Friends; ’Tis Not Too Late To Build A Better World -- Acknowledgments -- References -- Index restricted access http://purl.org/coar/access_right/c_16ec online access with authorization star The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren’t the interests of the public supposed to supersede the pursuit of private profit?In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century. Although the Canadian government is supposed to regulate the industry to serve the needs of public health, waves of deregulatory reforms and intellectual property rights legislation have shifted the balance of power in favour of these companies’ quest for profit. Joel Lexchin offers a series of recommendations to tip the scale back in the public’s favour. This enlightening work is the first book that deals exclusively with the pharmaceutical industry in Canada in over thirty years. Mode of access: Internet via World Wide Web. In English. Description based on online resource; title from PDF title page (publisher's Web site, viewed 24. Aug 2021) Drug development Government policy Canada. Pharmaceutical industry Government policy Canada. Prescription pricing Government policy Canada. Profit Government policy Canada. HEALTH & FITNESS / Health Care Issues. bisacsh Title is part of eBook package: De Gruyter University of Toronto Press Complete eBook-Package 2016 9783110665956 https://doi.org/10.3138/9781442619609 https://www.degruyter.com/isbn/9781442619609 Cover https://www.degruyter.com/cover/covers/9781442619609.jpg |
language |
English |
format |
eBook |
author |
Lexchin, Joel, Lexchin, Joel, |
spellingShingle |
Lexchin, Joel, Lexchin, Joel, Private Profits versus Public Policy : The Pharmaceutical Industry and the Canadian State / Frontmatter -- Contents -- List Of Boxes, Figures, And Tables -- Preface -- Abbreviations -- Private Profits Versus Public Policy The Pharmaceutical Industry And The Canadian State -- Introduction: Why Do We Care About The Pharmaceutical Industry In Canada? -- 1.(De)Regulation Through Cooperation -- 2. Biased Testing, Hidden Results, And The Regulation Of Clinical Trials -- 3. Approving New Drugs: Better Or Just More? -- 4. Regulating Promotion Or Licensing Deception? -- 5. Health Canada And Drug Safety: How Safe Are We? -- 6. Is Intellectual Property A Right? -- 7. How Revenue Is Generated: Prices, Volume, Mix, And Overall Spending -- 8. Who Gets The Value From Research And Development? -- 9. Canada, The Pharmaceutical Industry, And Access To Medicines In The Global South -- 10. Courage, My Friends; ’Tis Not Too Late To Build A Better World -- Acknowledgments -- References -- Index |
author_facet |
Lexchin, Joel, Lexchin, Joel, |
author_variant |
j l jl j l jl |
author_role |
VerfasserIn VerfasserIn |
author_sort |
Lexchin, Joel, |
title |
Private Profits versus Public Policy : The Pharmaceutical Industry and the Canadian State / |
title_sub |
The Pharmaceutical Industry and the Canadian State / |
title_full |
Private Profits versus Public Policy : The Pharmaceutical Industry and the Canadian State / Joel Lexchin. |
title_fullStr |
Private Profits versus Public Policy : The Pharmaceutical Industry and the Canadian State / Joel Lexchin. |
title_full_unstemmed |
Private Profits versus Public Policy : The Pharmaceutical Industry and the Canadian State / Joel Lexchin. |
title_auth |
Private Profits versus Public Policy : The Pharmaceutical Industry and the Canadian State / |
title_alt |
Frontmatter -- Contents -- List Of Boxes, Figures, And Tables -- Preface -- Abbreviations -- Private Profits Versus Public Policy The Pharmaceutical Industry And The Canadian State -- Introduction: Why Do We Care About The Pharmaceutical Industry In Canada? -- 1.(De)Regulation Through Cooperation -- 2. Biased Testing, Hidden Results, And The Regulation Of Clinical Trials -- 3. Approving New Drugs: Better Or Just More? -- 4. Regulating Promotion Or Licensing Deception? -- 5. Health Canada And Drug Safety: How Safe Are We? -- 6. Is Intellectual Property A Right? -- 7. How Revenue Is Generated: Prices, Volume, Mix, And Overall Spending -- 8. Who Gets The Value From Research And Development? -- 9. Canada, The Pharmaceutical Industry, And Access To Medicines In The Global South -- 10. Courage, My Friends; ’Tis Not Too Late To Build A Better World -- Acknowledgments -- References -- Index |
title_new |
Private Profits versus Public Policy : |
title_sort |
private profits versus public policy : the pharmaceutical industry and the canadian state / |
publisher |
University of Toronto Press, |
publishDate |
2018 |
physical |
1 online resource (384 p.) : 6 figures |
contents |
Frontmatter -- Contents -- List Of Boxes, Figures, And Tables -- Preface -- Abbreviations -- Private Profits Versus Public Policy The Pharmaceutical Industry And The Canadian State -- Introduction: Why Do We Care About The Pharmaceutical Industry In Canada? -- 1.(De)Regulation Through Cooperation -- 2. Biased Testing, Hidden Results, And The Regulation Of Clinical Trials -- 3. Approving New Drugs: Better Or Just More? -- 4. Regulating Promotion Or Licensing Deception? -- 5. Health Canada And Drug Safety: How Safe Are We? -- 6. Is Intellectual Property A Right? -- 7. How Revenue Is Generated: Prices, Volume, Mix, And Overall Spending -- 8. Who Gets The Value From Research And Development? -- 9. Canada, The Pharmaceutical Industry, And Access To Medicines In The Global South -- 10. Courage, My Friends; ’Tis Not Too Late To Build A Better World -- Acknowledgments -- References -- Index |
isbn |
9781442619609 9783110665956 |
callnumber-first |
H - Social Science |
callnumber-subject |
HD - Industries, Land Use, Labor |
callnumber-label |
HD9670 |
callnumber-sort |
HD 49670 C22 |
geographic_facet |
Canada. |
url |
https://doi.org/10.3138/9781442619609 https://www.degruyter.com/isbn/9781442619609 https://www.degruyter.com/cover/covers/9781442619609.jpg |
illustrated |
Not Illustrated |
dewey-hundreds |
300 - Social sciences |
dewey-tens |
330 - Economics |
dewey-ones |
338 - Production |
dewey-full |
338.4/761510971 |
dewey-sort |
3338.4 9761510971 |
dewey-raw |
338.4/761510971 |
dewey-search |
338.4/761510971 |
doi_str_mv |
10.3138/9781442619609 |
work_keys_str_mv |
AT lexchinjoel privateprofitsversuspublicpolicythepharmaceuticalindustryandthecanadianstate |
status_str |
n |
ids_txt_mv |
(DE-B1597)498620 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Title is part of eBook package: De Gruyter University of Toronto Press Complete eBook-Package 2016 |
is_hierarchy_title |
Private Profits versus Public Policy : The Pharmaceutical Industry and the Canadian State / |
container_title |
Title is part of eBook package: De Gruyter University of Toronto Press Complete eBook-Package 2016 |
_version_ |
1806143665234509824 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04079nam a22005175i 4500</leader><controlfield tag="001">9781442619609</controlfield><controlfield tag="003">DE-B1597</controlfield><controlfield tag="005">20210824034702.0</controlfield><controlfield tag="006">m|||||o||d||||||||</controlfield><controlfield tag="007">cr || ||||||||</controlfield><controlfield tag="008">210824t20182016onc fo d z eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781442619609</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3138/9781442619609</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-B1597)498620</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-B1597</subfield><subfield code="b">eng</subfield><subfield code="c">DE-B1597</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">onc</subfield><subfield code="c">CA-ON</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">HD9670.C22</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA028000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">338.4/761510971</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lexchin, Joel, </subfield><subfield code="e">author.</subfield><subfield code="4">aut</subfield><subfield code="4">http://id.loc.gov/vocabulary/relators/aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Private Profits versus Public Policy :</subfield><subfield code="b">The Pharmaceutical Industry and the Canadian State /</subfield><subfield code="c">Joel Lexchin.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Toronto : </subfield><subfield code="b">University of Toronto Press, </subfield><subfield code="c">[2018]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (384 p.) :</subfield><subfield code="b">6 figures</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="b">PDF</subfield><subfield code="2">rda</subfield></datafield><datafield tag="505" ind1="0" ind2="0"><subfield code="t">Frontmatter -- </subfield><subfield code="t">Contents -- </subfield><subfield code="t">List Of Boxes, Figures, And Tables -- </subfield><subfield code="t">Preface -- </subfield><subfield code="t">Abbreviations -- </subfield><subfield code="t">Private Profits Versus Public Policy The Pharmaceutical Industry And The Canadian State -- </subfield><subfield code="t">Introduction: Why Do We Care About The Pharmaceutical Industry In Canada? -- </subfield><subfield code="t">1.(De)Regulation Through Cooperation -- </subfield><subfield code="t">2. Biased Testing, Hidden Results, And The Regulation Of Clinical Trials -- </subfield><subfield code="t">3. Approving New Drugs: Better Or Just More? -- </subfield><subfield code="t">4. Regulating Promotion Or Licensing Deception? -- </subfield><subfield code="t">5. Health Canada And Drug Safety: How Safe Are We? -- </subfield><subfield code="t">6. Is Intellectual Property A Right? -- </subfield><subfield code="t">7. How Revenue Is Generated: Prices, Volume, Mix, And Overall Spending -- </subfield><subfield code="t">8. Who Gets The Value From Research And Development? -- </subfield><subfield code="t">9. Canada, The Pharmaceutical Industry, And Access To Medicines In The Global South -- </subfield><subfield code="t">10. Courage, My Friends; ’Tis Not Too Late To Build A Better World -- </subfield><subfield code="t">Acknowledgments -- </subfield><subfield code="t">References -- </subfield><subfield code="t">Index</subfield></datafield><datafield tag="506" ind1="0" ind2=" "><subfield code="a">restricted access</subfield><subfield code="u">http://purl.org/coar/access_right/c_16ec</subfield><subfield code="f">online access with authorization</subfield><subfield code="2">star</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren’t the interests of the public supposed to supersede the pursuit of private profit?In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century. Although the Canadian government is supposed to regulate the industry to serve the needs of public health, waves of deregulatory reforms and intellectual property rights legislation have shifted the balance of power in favour of these companies’ quest for profit. Joel Lexchin offers a series of recommendations to tip the scale back in the public’s favour. This enlightening work is the first book that deals exclusively with the pharmaceutical industry in Canada in over thirty years.</subfield></datafield><datafield tag="538" ind1=" " ind2=" "><subfield code="a">Mode of access: Internet via World Wide Web.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">In English.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Description based on online resource; title from PDF title page (publisher's Web site, viewed 24. Aug 2021)</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug development</subfield><subfield code="x">Government policy</subfield><subfield code="z">Canada.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Government policy</subfield><subfield code="z">Canada.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Prescription pricing</subfield><subfield code="x">Government policy</subfield><subfield code="z">Canada.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Profit</subfield><subfield code="x">Government policy</subfield><subfield code="z">Canada.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / Health Care Issues.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Title is part of eBook package:</subfield><subfield code="d">De Gruyter</subfield><subfield code="t">University of Toronto Press Complete eBook-Package 2016</subfield><subfield code="z">9783110665956</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3138/9781442619609</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.degruyter.com/isbn/9781442619609</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="3">Cover</subfield><subfield code="u">https://www.degruyter.com/cover/covers/9781442619609.jpg</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">978-3-11-066595-6 University of Toronto Press Complete eBook-Package 2016</subfield><subfield code="b">2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV-deGruyter-alles</subfield></datafield></record></collection> |